NCT07439458 Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity
| NCT ID | NCT07439458 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riga Stradins University |
| Condition | Acute Exercise |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-04-01 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer has emerged as a prominent cause of mortality in the 21st century, with breast cancer (BC) being the most diagnosed malignancy. Multidisciplinary cancer management has improved survival chances, but side effects and long-term consequences of treatments have significant implications for cancer survivors' health-related quality of life. Exercise is increasingly considered and used in cancer treatment and follow-up. However, studies demonstrating the biological mechanisms underlying the anticarcinogenic effects (ACE) of exercise are insufficient to justify the most appropriate physical activity for different clinical scenarios. Achieving scientific excellence in understanding the ACE of exercise in cancer management is critical to optimize treatment and enhance patients' quality of life.
Eligibility Criteria
Inclusion Criteria (intervention group): * Reproductive age (premenopausal); * Diagnosis of Stage II-III Triple-Negative Breast Cancer (TNBC) (negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)); * Timeframe of 3 to 9 months after completion of surgery, adjuvant chemotherapy, radiation therapy, and/or immunotherapy; * Physician-certified (cardiologist) physical fitness for exercise testing, supported by echocardiography (ECHO). Inclusion Criteria (control group): * Reproductive age (premenopausal); * No current or prior diagnosis of any type of cancer; * Matched by age, body constitution, and physical fitness to the breast cancer participant group. Exclusion Criteria: * Pregnancy; * Autoimmune diseases (e.g., thyroiditis, inflammatory bowel disease, atopic dermatitis, etc.); * Endocrine disorders (e.g., metabolic syndrome, diabetes); * Cardiovascular diseases; * Diagnosis of any other type of oncological disease; * Any condition for which physical activity is contraindicated (e.g., asthma, COPD, spinal disc herniation, severe iron deficiency anemia).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07439458 clinical trial?
This trial is open to female participants only, aged 35 Years or older, studying Acute Exercise. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07439458 currently recruiting?
Yes, NCT07439458 is actively recruiting participants. Contact the research team at Dace.Reihmane@rsu.lv for enrollment information.
Where is the NCT07439458 trial being conducted?
This trial is being conducted at Riga, Latvia.
Who is sponsoring the NCT07439458 clinical trial?
NCT07439458 is sponsored by Riga Stradins University. The trial plans to enroll 40 participants.